You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
德琪醫藥-B(06996.HK)實體瘤藥物ATG-101完成首例中國患者給藥
阿思達克 08-03 11:07
德琪醫藥-B(06996.HK)宣布,旗下新型PD-L1/4-1BB雙特異性抗體產品ATG-101,單藥用於治療晚期或轉移性實體瘤及B細胞非霍奇金淋巴瘤(B-NHL)患者的一期臨床試驗,近日已完成首例中國患者給藥。 該項臨床研究的牽頭單位為上海市東方醫院,研究將在內地4家研究中心開展。該項開放性、多中心一期研究旨在評估靜脈注射/滴注給藥的ATG-101單藥用於治療晚期或轉移性實體瘤及B-NHL的安全性和耐受性。 德琪醫藥首席醫學官Kevin Lynch表示,ATG-101有激活衰竭T細胞,將「冷腫瘤」向「熱腫瘤」轉化的能力,預示著對於復發、耐藥的腫瘤患者的治療具有廣泛的應用潛力,有望成為一款同類最佳藥物。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account